MCID: PRP016
MIFTS: 49

Paraplegia malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Paraplegia

About this section

Aliases & Descriptions for Paraplegia:

Name: Paraplegia 11 48 39 13 68
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 48
 
Paraplegia, Lower 11

Classifications:



External Ids:

Disease Ontology11 DOID:607
ICD1030 G82.2, G82.20
ICD9CM32 344.1
SNOMED-CT62 155031004, 60389000
MeSH39 D010264
NCIt45 C50687

Summaries for Paraplegia

About this section
Wikipedia:71 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

MalaCards based summary: Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 11 and spastic paraplegia 13, and has symptoms including hemiparesis, hemiplegia and ophthalmoplegia. An important gene associated with Paraplegia is SPG7 (SPG7, Paraplegin Matrix AAA Peptidase Subunit), and among its related pathways is Endocytosis. Affiliated tissues include spinal cord, brain and bone, and related mouse phenotypes are behavior/neurological and nervous system.

Related Diseases for Paraplegia

About this section

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 429)
idRelated DiseaseScoreTop Affiliating Genes
1spastic paraplegia 1133.3CYP7B1, SPG7
2spastic paraplegia 1332.5L1CAM, SPAST, SPG11
3hereditary spastic paraplegia12.3
4spastic paraplegia 712.1
5spastic paraplegia 412.1
6spastic paraplegia 72, autosomal recessive12.1
7silver spastic paraplegia syndrome12.1
8spastic paraplegia 812.1
9spastic paraplegia 3a, autosomal dominant12.1
10spastic paraplegia, optic atrophy, and neuropathy12.1
11spastic paraplegia 212.1
12spastic paraplegia 3a12.1
13spastic paraplegia 49, autosomal recessive12.1
14spastic paraplegia 11, autosomal recessive12.1
15spastic paraplegia 4, autosomal dominant12.1
16spastic paraplegia 39, autosomal recessive12.1
17spastic paraplegia 5a, autosomal recessive12.0
18spastic paraplegia 2, x-linked12.0
19spastic paraplegia 54, autosomal recessive12.0
20troyer syndrome12.0
21spastic paraplegia 15, autosomal recessive12.0
22spastic paraplegia 10, autosomal dominant12.0
23spastic paraplegia 9a, autosomal dominant12.0
24spastic paraplegia 30, autosomal recessive12.0
25spastic paraplegia 56, autosomal recessive12.0
26spastic paraplegia 46, autosomal recessive12.0
27spastic paraplegia 28, autosomal recessive12.0
28spastic paraplegia 35, autosomal recessive12.0
29spastic paraplegia 7, autosomal recessive12.0
30spastic paraplegia 43, autosomal recessive12.0
31spastic paraplegia 6312.0
32spastic paraplegia 45, autosomal recessive12.0
33spastic paraplegia 6, autosomal dominant12.0
34spastic paraplegia 18, autosomal recessive12.0
35spastic paraplegia 8, autosomal dominant12.0
36spastic paraplegia 26, autosomal recessive12.0
37spastic paraplegia 61, autosomal recessive12.0
38spastic paraplegia 12, autosomal dominant12.0
39spastic paraplegia 1512.0
40spastic paraplegia 57, autosomal recessive12.0
41spastic paraplegia 44, autosomal recessive12.0
42spastic paraplegia 31, autosomal dominant12.0
43spastic paraplegia 42, autosomal dominant12.0
44spastic paraplegia 48, autosomal recessive12.0
45spastic paraplegia 53, autosomal recessive12.0
46spastic paraplegia 55, autosomal recessive12.0
47spastic paraplegia 7512.0
48spastic paraplegia 9b, autosomal recessive12.0
49spastic paraplegia 3112.0
50spastic paraplegia 13, autosomal dominant12.0

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN):


Hypertension, EssentialProstate Cancer
Multiple Sclerosis, Disease Progression, Modifier ofOsteoporosis
Deficiency AnemiaHeart Disease
Protein-Energy MalnutritionNeurogenic Bladder
Acute CystitisSpinal Cord Disease
Vascular MyelopathyParalytic Ileus
Decubitus Ulcer

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to paraplegia

Symptoms & Phenotypes for Paraplegia

About this section

UMLS symptoms related to Paraplegia:


hemiparesis, hemiplegia, ophthalmoplegia, paresis, paraparesis, todd paralysis, paraplegia, ataxic, quadriparesis, monoparesis, paraplegia, cerebral, paraplegia, spinal, paraparesis, cerebral, paraparesis, spinal, monoplegia of lower limb affecting unspecified side, paraplegia, flaccid, paraparesis, chronic progressive, flaccid quadriplegia, paresis anal sphincter, paralysis of left leg only, paralysis of right leg only, nonmoving limbs (paralysis), nonmoving limbs affecting both legs

MGI Mouse Phenotypes related to Paraplegia according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053866.9ATL1, CYP7B1, DDHD2, HSPD1, KIF5A, L1CAM
2MP:00036316.6DDHD2, HSPD1, KIF5A, L1CAM, PLP1, PNPLA6

Drugs & Therapeutics for Paraplegia

About this section

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 100)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Acetazolamideapproved, vet_approvedPhase 47559-66-51986
Synonyms:
1424-27-7 (mono-hydrochloride salt)
1yda
1ydb
1ydd
1zsb
2-acetylamino-1,3,4-Thiadiazole-5-sulfonamide
2h4n
3czv
4-Diamox
5-ACETAMIDO-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulfonamide
5661-25-6
59-66-5
8017-69-4
A 6011
A6011_SIAL
A6011_SIGMA
AB00051906
AC-12779
AC1L1CO5
AI3-52458
AKOS000715163
Acetadiazol
Acetamidothiadiazolesulfonamide
Acetamox
Acetazolam
Acetazolamid
Acetazolamida
Acetazolamida [INN-Spanish]
Acetazolamide (AAZ)
Acetazolamide (JP15/USP/INN)
Acetazolamide Apotex Brand
Acetazolamide Chiesi Brand
Acetazolamide Dioptic Brand
Acetazolamide Grin Brand
Acetazolamide ICN Brand
Acetazolamide Jumer Brand
Acetazolamide Llorens Brand
Acetazolamide Medphano Brand
Acetazolamide Novopharm Brand
Acetazolamide Orion Brand
Acetazolamide Sodium
Acetazolamide Sodium, (Sterile)
Acetazolamide Wassermann Brand
Acetazolamide [INN:BAN:JAN]
Acetazolamide, Monosodium Salt
Acetazolamidum
Acetazolamidum [INN-Latin]
Acetazolamine
Acetazoleamide
Acetozalamide
Acétazolamide
Ak Zol
Ak-Zol
AkZol
Apo Acetazolamide
Apo-Acetazolamide
ApoAcetazolamide
Apotex Brand of Acetazolamide
Atenezol
BAS 01585728
BIDD:GT0643
BPBio1_000007
BSPBio_000005
BSPBio_001788
C06805
C4H6N4O3S2
CAS-59-66-5
CCRIS 5811
CHEBI:27690
CHEMBL20
CID1986
CPD0-1626
CPD000058394
Carbonic Anhydrase Inhibitor 6063
Carbonic Anhydrase Inhibitor No. 6063
Carbonic anhydrase inhibitor 6063
Chiesi Brand of Acetazolamide
Ciba Vision Brand of Acetazolamide
Cidamex
D000086
D00218
DB00819
Dazamide
Defiltran
Dehydratin
Diacarb
Diakarb
Diamox
Diamox (TN)
Diamox Sequels
Didoc
Diluran
 
Dioptic Brand of Acetazolamide
Diuramid
Diuramide
Diureticum-Holzinger
Diureticum-holzinger
Diuriwas
Diutazol
DivK1c_000017
Donmox
Duiramid
EINECS 200-440-5
EU-0100039
Edemox
Eumicton
Fonurit
Glauconox
Glaumox
Glaupax
Glupax
Grin Brand of Acetazolamide
HMS1568A07
HMS1920A05
HMS2091G05
HMS500A19
HSDB 3002
Huma Zolamide
Huma-Zolamide
HumaZolamide
I09-0425
ICN Brand of Acetazolamide
IDI1_000017
Jumer Brand of Acetazolamide
KBio1_000017
KBio2_000358
KBio2_002926
KBio2_005494
KBio3_001288
KBioGR_000558
KBioSS_000358
LS-10227
Llorens Brand of Acetazolamide
Lopac-A-6011
Lopac0_000039
MLS000028435
MLS001148438
Medphano Brand of Acetazolamide
MolPort-001-783-578
Monosodium Salt Acetazolamide
N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
NCGC00015074-01
NCGC00015074-02
NCGC00015074-03
NCGC00015074-06
NCGC00015074-11
NCGC00023455-03
NCGC00023455-04
NCGC00023455-05
NCGC00023455-06
NCGC00023455-07
NINDS_000017
NSC 145177
NSC145177
Natrionex
Nephramid
Nephramide
Novopharm Brand of Acetazolamide
Orion Brand of Acetazolamide
Phonurit
Prestwick0_000003
Prestwick1_000003
Prestwick2_000003
Prestwick3_000003
Prestwick_4
SAM002554883
SBB056640
SK-acetazolamide
SMR000058394
SPBio_000004
SPBio_001926
SPECTRUM1500102
Sk-Acetazolamide
Spectrum2_000082
Spectrum3_000284
Spectrum4_000139
Spectrum5_000738
Spectrum_000018
Storz Brand of Acetazolamide Preparation
Storzolamide
UNII-O3FX965V0I
Vetamox
WLN: T5NN DSJ CSZW EMV1
Wassermann Brand of Acetazolamide
Wyeth Brand of Acetazolamide Preparation
acetazolamide
2Natriuretic AgentsPhase 41645
3diureticsPhase 41372
4AnticonvulsantsPhase 42620
5Carbonic Anhydrase InhibitorsPhase 4179
6
Minocyclineapproved, investigationalPhase 2, Phase 322410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
7
AcetylcholineapprovedPhase 2, Phase 377651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
8Anti-Bacterial AgentsPhase 2, Phase 310884
9Anti-Infective AgentsPhase 2, Phase 321402
10Cholinergic AgentsPhase 2, Phase 33846
11Fibrin Tissue AdhesivePhase 2, Phase 3, Phase 1145
12Neurotransmitter AgentsPhase 2, Phase 3, Phase 117734
13Botulinum ToxinsPhase 2, Phase 3669
14CortivazolPhase 33
15Anti-Inflammatory AgentsPhase 3, Phase 210355
16
DopamineapprovedPhase 1, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
17
Buspironeapproved, investigationalPhase 1, Phase 24536505-84-72477
Synonyms:
36505-84-7
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
AB00053432
AC1L1DRN
AKOS002313325
Ansial
Ansiced
Anxiron
Axoren
BAS 00928841
BIDD:GT0519
BPBio1_000547
BPBio1_001403
BRD-K93461745-001-01-5
BRD-K93461745-003-03-7
BRN 0964904
BSPBio_000497
Bespar
Biomol-NT_000108
Buspiron
Buspirona
Buspirona [INN-Spanish]
Buspirone
Buspirone (INN)
Buspirone [INN:BAN]
Buspirone-MDTS
Buspironum
Buspironum [INN-Latin]
Buspisal
C06861
C13H21NO2.C9H14N4
CAS-33386-08-2
CHEBI:3223
CHEMBL49
 
CID2477
D07593
DB00490
DivK1c_000921
EINECS 253-072-2
Gen-Buspirone
Gen-Buspirone (TN)
HMS2090K19
IDI1_000921
KBio1_000921
KBio2_002236
KBio2_004804
KBio2_007372
KBioSS_002236
L001110
LS-22723
Lopac-B-7148
Lopac0_000223
MJ-9022-1
MolPort-002-539-709
N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide
NCGC00015162-01
NCGC00015162-06
NCGC00016820-01
NCGC00024905-01
NCGC00024905-02
NCGC00024905-03
NINDS_000921
Prestwick0_000369
Prestwick1_000369
Prestwick2_000369
Prestwick3_000369
SPBio_002418
STK086268
STOCK1S-11244
Spectrum_001756
Tocris-0962
UNII-TK65WKS8HL
buspirone
18
CarbidopaapprovedPhase 1, Phase 217728860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
19
LevodopaapprovedPhase 1, Phase 238859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
20
chenodeoxycholic acidapprovedPhase 232474-25-910133
Synonyms:
(+)-chenodeoxycholate
(+)-chenodeoxycholic acid
(3a,5b,7a)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7a)-3,7-dihydroxy-cholan-24-oic acid
3a,7a-Dihydroxy-5b,14a,17b-cholanate
3a,7a-Dihydroxy-5b,14a,17b-cholanic acid
3a,7a-Dihydroxy-5b-cholan-24-oate
3a,7a-Dihydroxy-5b-cholan-24-oic acid
3a,7a-Dihydroxy-5b-cholanate
3a,7a-Dihydroxy-5b-cholanic acid
3alpha,7alpha-Dihydroxy-5beta-cholanic acid
7a-Hydroxy-desoxycholsaeure
 
7alpha-Hydroxylithocholic acid
Anthropodeoxycholic acid
Anthropodesoxycholic acid
CDCA
Chenic acid
Chenix
Chenocholic acid
Chenodeoxycholate
Chenodeoxycholic acid
Chenodesoxycholic acid
Chenodesoxycholsaeure
Chenodiol
Gallodesoxycholic acid
21
Resveratrolexperimental, investigationalPhase 2112501-36-0, 955365-80-724856436, 445154
Synonyms:
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol
(E)-resveratrol
 
3,4',5-Stilbenetriol
3,4',5-Trihydroxystilbene
3,4',5-trihydroxy-stilbene
MK-1775
trans-3,4',5 - Trihydroxystilbene
trans-3,4',5-trihydroxystilbene
trans-Resveratrol
22Dopamine AgentsPhase 1, Phase 23759
23Serotonin AgentsPhase 1, Phase 23102
24Central Nervous System DepressantsPhase 1, Phase 212806
25AnalgesicsPhase 211287
26Tranquilizing AgentsPhase 1, Phase 24164
27
SerotoninPhase 1, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
28Psychotropic DrugsPhase 1, Phase 26279
29Pharmaceutical SolutionsPhase 27793
30incobotulinumtoxinAPhase 2635
31HemagglutininsPhase 2118
32Carbidopa, levodopa drug combinationPhase 1, Phase 2120
33abobotulinumtoxinAPhase 2626
34Neuromuscular AgentsPhase 21129
35Botulinum Toxins, Type APhase 2630
36onabotulinumtoxinAPhase 2626
37Antiparkinson AgentsPhase 1, Phase 21527
38Anti-Anxiety AgentsPhase 1, Phase 21816
39Peripheral Nervous System AgentsPhase 222776
40Hypolipidemic AgentsPhase 22721
41Lipid Regulating AgentsPhase 22702
42AntimetabolitesPhase 211774
43Gastrointestinal AgentsPhase 28109
44Protective AgentsPhase 27190
45Platelet Aggregation InhibitorsPhase 22419
46LaxativesPhase 2520
47Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 21956
48Anti-Inflammatory Agents, Non-SteroidalPhase 24295
49Analgesics, Non-NarcoticPhase 26260
50CatharticsPhase 2520

Interventional clinical trials:

(show top 50)    (show all 91)
idNameStatusNCT IDPhase
1Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery SurgeryUnknown statusNCT01889498Phase 4
2Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord LesionsCompletedNCT01208584Phase 4
3Effect of Heat Exposure on Cognition in Persons With TetraplegiaRecruitingNCT02488824Phase 4
4Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care InvolvementUnknown statusNCT01813240Phase 2, Phase 3
5Retraining Walking After Spinal Cord InjuryUnknown statusNCT00059553Phase 2, Phase 3
6Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal SciaticaRecruitingNCT02151045Phase 3
7Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic ParaplegiaActive, not recruitingNCT02604186Phase 2, Phase 3
8Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord InjuryWithdrawnNCT01569360Phase 3
9Cethrin in Acute Cervical Spinal Cord InjuryWithdrawnNCT02053883Phase 2, Phase 3
10Spinal Cord Injury Leg RehabilitationCompletedNCT01498991Phase 1, Phase 2
11Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral PalsyCompletedNCT02188277Phase 2
12The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI)CompletedNCT01349478Phase 1, Phase 2
13A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord InjuriesCompletedNCT00500812Phase 1, Phase 2
14Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord InjuryCompletedNCT01484184Phase 1, Phase 2
15Feasibility of Telephone Counseling to Increase Physical Fitness in SCIRecruitingNCT02225028Phase 2
16Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5Active, not recruitingNCT02314208Phase 2
17Neural Stem Cell Transplantation in Traumatic Spinal Cord InjuryActive, not recruitingNCT02326662Phase 1, Phase 2
18Epidural Stimulation After Neurologic DamageNot yet recruitingNCT03026816Phase 2
19Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord InjuryNot yet recruitingNCT02574585Phase 2
20Autologous Incubated Macrophages for Patients With Complete Spinal Cord InjuriesSuspendedNCT00073853Phase 2
21Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue.TerminatedNCT00429013Phase 2
22SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic ParaplegiasUnknown statusNCT00140829Phase 1
23Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar DegenerationsUnknown statusNCT00136630Phase 1
24Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in ParaplegiaCompletedNCT00108043Phase 1
25Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCICompletedNCT01739023Phase 1
26Use of Interactive Gaming for Enhanced Function After Spinal Cord InjuryCompletedNCT01537978Phase 1
27Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic ParaplegiaCompletedNCT01909154Phase 1
28The ReWalk Exoskeletal Walking System for Persons With ParaplegiaRecruitingNCT01454570Phase 1
29A Neuroprosthesis for Seated Posture and BalanceRecruitingNCT01474148Phase 1
30The Safety of ahSC in Chronic SCI With RehabilitationRecruitingNCT02354625Phase 1
31Improving Ambulatory Community Access After ParalysisActive, not recruitingNCT01570816Phase 1
32Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and EpilepsiesTerminatedNCT00142363Phase 1
33Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.Unknown statusNCT02042508
34Reciprocating Gait Orthoses for Paraplegia PatientsUnknown statusNCT02227407
35Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During PropulsionUnknown statusNCT00785278
36Abdominal Functional Electrical Stimulation in TetraplegiaUnknown statusNCT00202631
37Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord InjuryUnknown statusNCT01386762Early Phase 1
38Body Composition Assessment in Spinal Cord InjuryUnknown statusNCT00957762
39Paraplegic Cycling: Improving Health After Spinal Cord InjuryUnknown statusNCT00204100
40Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral SclerosisCompletedNCT00023075
41Effects of Exercise in People With ParaplegiaCompletedNCT01203150
42Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed OsteoporosisCompletedNCT00838838
43A Study Testing Safety and Tolerance of the ReWalk Exoskeleton SuitCompletedNCT00627107
44Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)CompletedNCT01251549
45Exercise to Reduce Obesity in Spinal Cord InjuryCompletedNCT00270855
46Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)CompletedNCT00385918
47Medico-economical Impact of the Brindley Neurosurgical Technique in FranceCompletedNCT00221767
48Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord InjuriesCompletedNCT00004445
49Evaluation of the GORE® EXCLUDER® Iliac Branch EndoprosthesisCompletedNCT01883999
50Intrathecal Morphine on Transcranial Electric Motor-Evoked PotentialsCompletedNCT00596609

Search NIH Clinical Center for Paraplegia


Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

About this section

Anatomical Context for Paraplegia

About this section

MalaCards organs/tissues related to Paraplegia:

36
Spinal cord, Brain, Bone, Testes, Bone marrow, Colon, Tongue

Publications for Paraplegia

About this section

Articles related to Paraplegia:

(show top 50)    (show all 1236)
idTitleAuthorsYear
1
Clinical and genetic study of hereditary spastic paraplegia in Canada. (27957547)
2017
2
Posterior-only vertebral column resection for revision surgery in post-laminectomy rotokyphoscoliosis associated with late-onset paraplegia: A case report and literature review. (28072705)
2017
3
Beneficial effects of rapamycin in a Drosophila model for hereditary spastic paraplegia. (27909242)
2017
4
ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. (27738760)
2017
5
A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia. (28000352)
2017
6
Exome sequencing reveals two FA2H mutations in a family with a complicated form of Hereditary Spastic Paraplegia and psychiatric impairments. (28017243)
2017
7
Genetic and phenotypic characterization of complex hereditary spastic paraplegia. (27217339)
2016
8
A novel SPAST frameshift mutation in a Chinese family with hereditary spastic paraplegia. (27629539)
2016
9
Establishment of SPAST mutant induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia (HSP) patient. (27789400)
2016
10
Defining the genetic basis of early onset hereditary spastic paraplegia using whole genome sequencing. (27679996)
2016
11
Novel De Novo Mutations in KIF1A as a Cause of Hereditary Spastic Paraplegia With Progressive Central Nervous System Involvement. (27034427)
2016
12
Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous Y275X mutation in CYP7B1 (SPG5). (27879220)
2016
13
Paraplegia after posterior fossa surgery in prone position: can we prevent it? (27942923)
2016
14
Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation. (27293921)
2016
15
Multiparametric 3T MRI evaluation of hereditary spastic paraplegia: A case report. (27857457)
2016
16
Rapid Neurological Recovery Following Partial Surgical Resection of Spinal Glioblastoma Multiforme in a Pediatric Patient Presenting With Complete Paraplegia. (27403775)
2016
17
Late-onset spastic paraplegia type 10 (SPG10) family presenting with bulbar symptoms and fasciculations mimicking amyotrophic lateral sclerosis. (27084214)
2016
18
Acute hemorrhagic paraplegia in a thoracic spinal hemangioblastoma after free diving. (27683699)
2016
19
Spontaneously developed paraplegia in a patient with Factor V Leiden mutation. (28053741)
2016
20
CYP2U1 mutations in two Iranian patients with activity induced dystonia, motor regression and spastic paraplegia. (27292318)
2016
21
Novel Genetic, Clinical, and Pathomechanistic Insights into TFG-Associated Hereditary Spastic Paraplegia. (27492651)
2016
22
Are low levels of 25(OH) vitamin D and testosterone clinically relevant in men with paraplegia? (27077579)
2016
23
A 23 years follow-up study identifies GLUT1 deficiency syndrome initially diagnosed as complicated hereditary spastic paraplegia. (27725288)
2016
24
Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hematopoietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach. (27110548)
2016
25
Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions. (27016404)
2016
26
Cognitive Impairment Involving Social Cognition in SPG4 Hereditary Spastic Paraplegia. (27688599)
2016
27
Conserved pharmacological rescue of hereditary spastic paraplegia-related phenotypes across model organisms. (26744324)
2016
28
Acute Paraplegia as a Result of Hemorrhagic Spinal Ependymoma Masked by Spinal Anesthesia: Case Report and Review of Literature. (27195260)
2016
29
Young Woman With Paraplegia Following a Motor Vehicle Crash. (27894643)
2016
30
Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. (27153400)
2016
31
A New Combined Technique Reducing the Risk of Paraplegia during Thoracoabdominal Aorta Replacement. (27050813)
2016
32
Complicated spastic paraplegia in patients with AP5Z1 mutations (SPG48). (27606357)
2016
33
Non-motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations. (26806216)
2016
34
SPG46 and SPG56 are rare causes of hereditary spastic paraplegia in China. (27553021)
2016
35
Paraplegia After Thoracic Epidural Steroid Injection. (27536909)
2016
36
KCNA2 mutations are rare in hereditary spastic paraplegia. (28019661)
2016
37
Tractor seating for operators with paraplegia. (27450642)
2016
38
Novel Mutations in Endoplasmic Reticulum Lipid Raft-associated Protein 2 Gene Cause Pure Hereditary Spastic Paraplegia Type 18. (27824013)
2016
39
Whole-genome sequencing of two probands with hereditary spastic paraplegia reveals novel splice-donor region variant and known pathogenic variant in SPG11. (27900367)
2016
40
Ischemia and reperfusion injury of the spinal cord: experimental strategies to examine postischemic paraplegia. (27127475)
2016
41
Acute aortic dissection presenting as painless paraplegia: a case report. (27089874)
2016
42
A Rare Complication of Tuberculosis: Acute Paraplegia. (27587940)
2016
43
Sudden onset of paraplegia secondary to an unusual presentation of pediatric synovial sarcoma. (27444286)
2016
44
A series of Greek children with pure hereditary spastic paraplegia: clinical features and genetic findings. (27260292)
2016
45
Spinal Epidural Abscess with Pregnancy Leading to Paraplegia. (27046967)
2016
46
Congenital-onset spastic paraplegia in a patient with TUBB4A mutation and mild hypomyelination. (27538619)
2016
47
The MicroRNA-224 Inhibitor Prevents Neuronal Apoptosis via Targeting Spastic Paraplegia 7 After Cerebral Ischemia. (27165196)
2016
48
Hereditary spastic paraplegia with a thin corpus callosum due to SPG11 mutation. (26755014)
2016
49
Acute myeloid leukemia presenting with complete paraplegia and bilateral total blindness due to central nervous system involvement. (28053737)
2016
50
Paraplegia as Manifestation of an Isolated Central Nervous System Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in a Woman with Acute Myelogenous Leukemia. (27625104)
2016

Variations for Paraplegia

About this section

Copy number variations for Paraplegia from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11705413155544315155572167Copy numberSLC33A1Paraplegias

Expression for genes affiliated with Paraplegia

About this section
Search GEO for disease gene expression data for Paraplegia.

Pathways for genes affiliated with Paraplegia

About this section

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.5KIF5A, SPG20, SPG21, ZFYVE27

GO Terms for genes affiliated with Paraplegia

About this section

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axon cytoplasmGO:190411510.9SPAST, SPG7
2midbodyGO:00304969.6SPAST, SPG20, ZFYVE26
3endoplasmic reticulumGO:00057839.5ATL1, PNPLA6, REEP1, RTN2, SPAST, ZFYVE27
4endoplasmic reticulum membraneGO:00057899.1ATL1, CYP7B1, PNPLA6, REEP1, SLC33A1, SPAST

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1anterograde axonal transportGO:000808910.4SPAST, SPG7
2lipid particle organizationGO:00343899.6DDHD2, SPG20

Sources for Paraplegia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet